Express Scripts — Cigna's pharmacy benefit manager — said Thursday that it will expand low-copay access to GLP-1 agonist weight-loss drugs for participants in some of the prescription drug ...

People with diabetes who used semaglutide or other GLP-1 agonists were also less likely to see a provider for depression.

The popular weight-loss and diabetes drugs could play a significant role not only in disease prevention, but possibly in ...

The GLP-1 boom is expected to transform the food industry, totally changing the way people eat. The market could be massive, with some predicting that it may be worth more than the iPhone was in its ...

GLP-1 weight loss patches are everywhere but do they actually work as these trendy patches promise Ozempic-like results without prescriptions ...

Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed ...

GLP-1 drugs have proved lifechanging for millions of Americans, but doctors say there are things people should consider before starting them. According to a new feature by the Washington Post ...

CHICAGO — Dapiglutide, a novel GLP-1/GLP-2 receptor agonist, was associated with body weight reductions of up to 8.3% at 13 weeks for patients with overweight or obesity in an early study ...

If you're looking for a top healthcare stock to buy that has much more upside in GLP-1, then going with Eli Lilly or Novo Nordisk can make much more sense at this stage.

A new tablet-based drug is showing great promise for both type 2 diabetes and obesity — and unlike existing GLP-1 medications, it doesn’t reduce appetite or cause muscle loss. Early studies ...

“While unpredictable GLP-1 medication access is frustrating, the good news is that our research shows effective weight loss can still be achieved if paired with appropriate lifestyle changes and ...

Could China’s New GLP-1 Drugs Beat Out Ozempic? GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver disease and type 2 ...